Q. Ping Dou

Q. Ping Dou, Ph.D.
540.1 Hudson Webber
4100 John R. Road
Detroit, MI 48201

Mentoring: Richard Arkwright ( Senior Student )

Research Interests:
Cancer Targeted Therapy, and Chemoprevention

Research Description:
The main objective in this laboratory is to discover molecular targets of natural products in pre-clinical studies, followed by validation in targeted cancer intervention clinical trials. Dr. Dou's laboratory is one of the first to report that proteasome inhibitors rapidly induce tumor cell apoptosis, selectively activate the cell death program in oncogene-transformed, but not normal or untransformed cells, and are able to trigger apoptotic death in human cancer cells that are resistant to various anticancer agents. Possible molecular mechanisms involve, at least in part, accumulation of the cyclin-dependent kinase inhibitor p27kip and the apoptosis inducer Bax. Dr. Dou's laboratory has also shown that some tea polyphenols and medicinal compounds potently and specifically inhibit the chymotrypsin-like activity of the proteasome in vitro and in vivo at physiological concentrations.

Furthermore, his laboratory has established, for the first time, a computational molecular model that shows how these natural compounds bind and target the proteasome chymotrypsin subunit. This innovative computational model has been validated by comparison of predicted and actual activities of various analogs, either naturally occurring or rationally designed and synthesized. Recently, Dr. Dou and collaborators have reported that certain copper-binding drugs (such as the antialcoholism drug Disulfiram) can convert the pro-angiogenic copper to a specific cancer cell death inducer. Disulfiram also promotes the conversion of carcinogenic cadmium to a proteasome inhibitor with pro-apoptotic activity in human cancer cells. Finally, environmental toxic organotins target the proteasome in human cells and proteasome inhibition by organotins contributes to their cellular toxicity.

Selected Publications:

Gambini V, Tilio M, Maina EW, Andreani C, Bartolacci C, Wang J, Iezzi M, Ferraro S, Ramadori AT, Simon OC, Pucciarelli S, Wu G, Dou QP, Marchini C, Galassi R, Amici A. In vitro and in vivo studies of gold(I) azolate/phosphane complexes for the treatment of basal like breast cancer. European Journal of Medicinal Chemistry 2018;155:418-27.

Ahmed ZSO, Li X, Li F, Cheaito HA, Patel K, Mosallam ESM, Elbargeesy GA, Dou QP. Computational and Biochemical Studies of Isothiocyanates as Inhibitors of Proteasomal Cysteine Deubiquitinases in Human Cancer Cells. Journal of Cellular Biochemistry 2018 Jul 17. [Epub ahead of print]

Neslund-Dudas CM, McBride RB, Kandegedara A, Rybicki BA, Kryvenko ON, Chitale D, Gupta N, Williamson SR, Rogers CG, Cordon-Cardo C, Rundle AG, Levin AM, Dou QP, Mitra B.  Association between cadmium and androgen receptor protein expression differs in prostate tumors of African American and European American men. J Trace Elem Med Biol. 2018;48:233-38.

Liao YN, Xia XH, Liu NN, Cai JY, Guo ZQ, Li YL, Jiang LL, Dou QP, Tang DL, Huang HB, and Liu JB.  Growth arrest and apoptosis induction in androgen receptor-positive human breast cancer cells by inhibition of USP14-mediated androgen receptor deubiquitination. Oncogene  2018;37:1896-910.

Patel K, Ahmed ZS, Huang X, Yang Q, Ekinci E, Neslund-Dudas CM, Mitra B, Elnady FA, Ahn YH, Yang H, Liu J, Dou QP. Discovering proteasome-associated DUB inhibitors for cancer therapy: Lessons learned from rational design, nature and old drug reposition. Future Med Chem. 2018;10:2087-108.

Li F, Wang Y, Li D, Chen Y, Qiao X, Fardous R, Lewandowski A, Liu JB, Chan TH, Dou QP. Perspectives on the recent developments with green tea polyphenols in drug discovery. Expert Opinion On Drug Discovery 2018;13:643-60.

Viola-Rhenalsa M, Patel KR, Jaimes-Santamaria L, Wu GJ, Liu JB and Dou QP. Recent Advances in Antabuse (Disulfiram): the importance of its metal-binding ability to its anticancer activity. Current Medicinal Chemistry 2018;25:506-24.

Soave CL, Guerin T, Liu JB and Dou QP. Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer and Metastasis Reviews 2017;36:717-36.

Chen X, Yang Q, Xiao L, Tang D, Dou QP and Liu JB. Metal-based proteasomal deubiquitinase inhibitors as potential anti-cancer agents. Cancer and Metastasis Reviews  2017;36:655-68.

Lucas S (co-first author), Soave C (co-first-author), Nabil G, Ahmed ZSO, Chen G, El-Banna HA, Dou QP (co-corresponding author) and Wang J (co-corresponding author). Pharmacological Inhibitors of NAD biosynthesis as potential anticancer agents. Recent Patents on Anti-Cancer Drug Discovery 2017;12:190-207.

Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou QP, Olsen J, Hajduch M, Cvek B, Deshaies RJ, Bartek J. Alcohol-abuse drug disulfiram targets cancer via p97 segregase adapter NPL4. Nature 2017;552:194-9.

Zhao C, Chen X, Yang C, Zang D, Lan X, Liao S, Zhang P, Wu J, Li X, Liu N, Liao Y, Huang H, Shi X, Jiang L, Liu X, Dou QP, Wang X, Liu J. Repurposing an antidandruff agent to treating cancer: zinc pyrithione inhibits tumor growth via targeting proteasome-associated deubiquitinases. ONCOTARGET 2017;8:13942-56.

Zhao C, Chen X, Zang D, Lan X, Liao S, Yang C, Zhang P, Wu J, Li X, Liu N, Liao Y, Huang H, Shi X, Jiang L, Liu X, Dou QP, Wang XJ, and Liu JB.  A novel nickel complex works as a proteasomal deubiquitinase inhibitor for cancer therapy. Oncogene 2016;35:5916-27.

Education and Training
PhD (1988): Rutgers University, New Jersey

Cancer Biology Courses Taught:
CB7460 Mechanism of Neoplasia: Alterations to Cellular Signaling